Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05952934 · ClinicalTrials.gov registry record · Phase 2
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
A Phase 2 study of Squamous Cell Carcinoma of Head and Neck, sponsored by University of Arkansas.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 6
- Study locations
NCT05952934 is a Phase 2 study of Squamous Cell Carcinoma of Head and Neck that is actively recruiting participants, run by University of Arkansas. The registered enrollment target is 100 participants, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (40% lower). The trial reports 6 study locations across 2 states.
The verdict
NCT05952934, a Phase 2 study of Squamous Cell Carcinoma of Head and Neck, is actively recruiting participants, sponsored by University of Arkansas.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 80 subjects are eligible for injection.
Conditions Studied
Interventions
- BIOLOGICAL 0.5 mL Candin®/injection
- OTHER Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)
Study Locations (6)
Arkansas
- Highlands Oncology Group, PA - Fayetteville
- University of Arkansas for Medical Sciences - Little Rock
- Highlands Oncology Group, PA - Rogers
- Highlands Oncology Group, PA - Springdale
New York
- Perlmutter Cancer Center at NYU Langone Health - Mineola
- Perlmutter Cancer Center at NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05952934
The ClinicalTrials.gov registry entry for NCT05952934 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (40% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 2 interventions - of which 0.5 mL Candin®/injection is the first listed.
NCT05952934 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Arkansas, New York.
Frequently Asked Questions
What is clinical trial NCT05952934 about?
NCT05952934 is a clinical study titled "Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence". This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the pl...
What is the current status of trial NCT05952934?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-02-12. Estimated completion is 2029-02-01.
What conditions does trial NCT05952934 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.
What interventions are being tested in trial NCT05952934?
The interventions under investigation include: 0.5 mL Candin®/injection (BIOLOGICAL), Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline) (OTHER).
Who is sponsoring clinical trial NCT05952934?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05952934 being conducted?
This trial has 6 study locations across Arkansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RECRUITING · Phase 2
-
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
RECRUITING · Phase 2
-
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
RECRUITING · Phase 2
-
Pembrolizumab Plus Olaparib in LA-HNSCC
ACTIVE NOT RECRUITING · Phase 2
-
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.